Establishment Of A Biomarker To Test Molecular Risk Of Gastric Cancer

Abstract

Less than 20% of patients live 5 years after a diagnosis of gastric cancer (GC). This is due to the advanced stage at the time of diagnosis. We have no markers to monitor therapy of cancer. This proposal aims to use next generation sequencing to find specific genetic changes in a persons tumour that can be used to monitor therapy. We aim to use the same technology to group patients into high-risk or low risk for development of GC. This will allow specific screening only for those at high-risk.

Related publications (1)

Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer

Sharon Pattison, Catherine Mitchell, Stephen Lade, Trevor Leong, Rita A Busuttil, Alex Boussioutas

2017-09-18